Kyverna Therapeutics, Inc. (KYTX)
NASDAQ:KYTX
Want to see KYTX full AI Analyst Report?
KYTX Stock Chart & Stats
$9.93
-$0.14(-3.63%)
At close: 4:00 PM EST
$9.93
-$0.14(-3.63%)
Day’s Range― - ―
52-Week Range$1.92 - $13.67
Previous CloseN/A
Volume87.17K
Average Volume (3M)658.87K
Market Cap
$586.87M
Enterprise Value$352.93M
Total Cash (Recent Filing)$279.25M
Total Debt (Recent Filing)$29.03M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,439,890
10 Day Avg. Volume664,385
30 Day Avg. Volume658,872
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.71
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-196.18
Enterprise Value/Ebitda-2.19
Forecast
1Y Price Target
$29.00Price Target Upside192.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Registrational CAR-T Clinical WinsRobust registrational data showing deep, durable single-dose responses and immunotherapy discontinuation across myasthenia gravis and stiff person syndrome materially improves the probability of regulatory approval and establishes potential first-in-class positioning, supporting a lasting commercial franchise in high-unmet-need neuroimmunology.
Board And Capital Markets ExpertiseAdding proven drug development and capital-markets veterans strengthens governance and execution capability during late-stage development and potential launch. Their experience should accelerate regulatory strategy, manufacturing scale-up decisions, and fundraising or M&A execution over the coming 2–6 months.
Low Financial LeverageVery low debt provides structural financial flexibility while Kyverna advances registrational programs, lowering near-term refinancing risk and preserving capacity to raise equity or strategic partnerships without heavy interest burden, a durable balance-sheet advantage amid prolonged development timelines.
Bears Say
Accelerating Cash BurnSteeply worsening operating cash outflows indicate mounting financing needs; sustained negative free cash flow increases reliance on external capital or partnerships. This structural cash-burn trend can force dilutive equity raises or deal terms that dilute existing holders and constrain strategic optionality.
No Revenue, Widening LossesAbsence of recurring revenue and rapidly expanding net losses reflect a stage-of-life business model that must convert clinical success into commercial sales to reach sustainability. Until launch and meaningful uptake, margins and profitability remain structurally negative, extending financing and execution risk.
Equity Dilution Risk From Incentive PoolExpanding inducement equity capacity and awarding sizable options to new executives signals ongoing reliance on equity compensation to attract talent and potentially raise funds. Over time this increases share count and dilution risk for existing investors, especially if coupled with further equity financings to cover cash burn.
Kyverna Therapeutics, Inc. News
KYTX FAQ
What was Kyverna Therapeutics, Inc.’s price range in the past 12 months?
Kyverna Therapeutics, Inc. lowest stock price was $1.92 and its highest was $13.67 in the past 12 months.
What is Kyverna Therapeutics, Inc.’s market cap?
Kyverna Therapeutics, Inc.’s market cap is $586.87M.
When is Kyverna Therapeutics, Inc.’s upcoming earnings report date?
Kyverna Therapeutics, Inc.’s upcoming earnings report date is May 19, 2026 which is in 26 days.
How were Kyverna Therapeutics, Inc.’s earnings last quarter?
Kyverna Therapeutics, Inc. released its earnings results on Mar 26, 2026. The company reported -$0.8 earnings per share for the quarter, beating the consensus estimate of -$0.851 by $0.051.
Is Kyverna Therapeutics, Inc. overvalued?
According to Wall Street analysts Kyverna Therapeutics, Inc.’s price is currently Undervalued.
Does Kyverna Therapeutics, Inc. pay dividends?
Kyverna Therapeutics, Inc. does not currently pay dividends.
What is Kyverna Therapeutics, Inc.’s EPS estimate?
Kyverna Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kyverna Therapeutics, Inc. have?
Kyverna Therapeutics, Inc. has 60,439,890 shares outstanding.
What happened to Kyverna Therapeutics, Inc.’s price movement after its last earnings report?
Kyverna Therapeutics, Inc. reported an EPS of -$0.8 in its last earnings report, beating expectations of -$0.851. Following the earnings report the stock price went down -2.864%.
Which hedge fund is a major shareholder of Kyverna Therapeutics, Inc.?
Currently, no hedge funds are holding shares in KYTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kyverna Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.00 (192.04% Upside)
$29.00 (192.04% Upside)
Blogger Sentiment
Bullish
KYTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
433.87%
12-Months-Change
Fundamentals
Return on Equity
-81.41%
Trailing 12-Months
Asset Growth
-3.77%
Trailing 12-Months
Company Description
Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
KYTX Stock 12 Month Forecast
Average Price Target
$29.00
▲(192.04% Upside)
Technical Analysis
Codexis
―
Heron Therapeutics
―
Silence Therapeutics
―
Atea Pharmaceuticals
―
Entrada Therapeutics Inc
―
Ownership Overview
23.37% Insiders
5.78% Mutual Funds
<0.01% Other Institutional Investors
66.52% Public Companies and Individual Investors